Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	54.67	40.38	299.01	90.8	82.3	58.9
Short-Term Investments	46.14	62.88	29.31	83.51	211.47	222.77
Cash & Cash Equivalents	100.81	103.26	328.32	174.3	293.77	281.66
Cash Growth	-58.36%	-68.55%	88.36%	-40.67%	4.30%	-44.35%
Receivables	14.66	17.47	16.79	14.07	69.67	50.57
Other Current Assets	8.82	12.81	8.36	61.5	29.9	6.25
Total Current Assets	124.29	133.54	353.46	249.87	393.34	338.49
Property, Plant & Equipment	44.08	45.36	52	53.35	59.68	59.25
Long-Term Investments	0	0	0	67.54	12.75	4.99
Other Long-Term Assets	202.93	203.1	201.94	4.07	3.28	6.11
Total Long-Term Assets	247.01	248.46	253.94	124.95	75.72	70.34
Total Assets	371.31	382	607.4	374.82	469.06	408.83
Accounts Payable	1.69	1.52	1.55	3.1	6.78	4.76
Deferred Revenue	0	0	0.19	0.41	11.87	38.34
Current Debt	4.06	3.92	6.75	17.44	29.2	17.61
Other Current Liabilities	15.91	19.32	20.22	37.64	75.72	51
Total Current Liabilities	21.66	24.77	28.72	58.59	123.57	111.7
Long-Term Debt	43.84	45.24	45.41	652.08	647.06	492.92
Other Long-Term Liabilities	100.94	99	91.48	2.73	2.18	28.05
Total Long-Term Liabilities	144.78	144.24	136.89	654.81	649.24	520.96
Total Liabilities	166.44	169	165.6	713.39	772.81	632.67
Total Debt	47.9	49.16	52.16	669.52	676.26	510.53
Debt Growth	-6.43%	-5.75%	-92.21%	-1.00%	32.46%	12.36%
Retained Earnings	-920.77	-909.1	-853.91	-1,726.04	-1,526.62	-1,248.6
Comprehensive Income	-0.04	-0.07	-0.02	0	0.05	0.15
Shareholders' Equity	204.87	213	441.8	-338.57	-303.75	-223.84
Net Cash / Debt	52.91	54.1	276.16	-495.22	-382.48	-228.86
Net Cash / Debt Growth	-72.29%	-80.41%	-	-	-	-
Net Cash Per Share	1.10	0.98	3.75	-7.13	-6.13	-4.12
Working Capital	102.63	108.77	324.75	191.28	269.77	226.79
Book Value Per Share	4.24	3.85	6.00	-4.87	-4.87	-4.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).